2011
DOI: 10.4065/mcp.2011.0128
|View full text |Cite
|
Sign up to set email alerts
|

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
35
0
1

Year Published

2011
2011
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 33 publications
(38 citation statements)
references
References 127 publications
(165 reference statements)
2
35
0
1
Order By: Relevance
“…However, according to at least one US Expert Panel the incremental expense is warranted in certain patients (5 ). The therapeutic value relative to the incremental cost of each of the measurements is currently under aggressive debate (5,56 ).…”
Section: Comparison Of Apo B Ita/ina and Ldl-p Methodsmentioning
confidence: 99%
“…However, according to at least one US Expert Panel the incremental expense is warranted in certain patients (5 ). The therapeutic value relative to the incremental cost of each of the measurements is currently under aggressive debate (5,56 ).…”
Section: Comparison Of Apo B Ita/ina and Ldl-p Methodsmentioning
confidence: 99%
“…Figure 5 shows the relationship between Apo B levels and CHD event rates in primary and secondary prevention studies of lipid-altering drug therapies. 160 Although subject selection was not based on Apo B for the majority of these studies, none of the trials showed a significant imbalance between groups for baseline Apo B concentration. Also, these studies varied with regard to the therapeutic regimen tested, clinical population, and Apo B assay used.…”
Section: Should Apo B Be a Target Of Therapy? If Not How Should Apo mentioning
confidence: 99%
“…High ApoB levels could potentially be of importance for contributing to an unfavourable cardiovascular profile in AN patients, although the prognostic role of lipid metabolism markers for the incidence of and mortality due to cardiovascular disease in AN is not yet clear because of a lack of longitudinal data (Jacobson, 2011). Therefore, further research on the beneficial role of weight gain in reducing ApoB levels and its relationship to the onset of cardiovascular events is needed in AN patients.…”
Section: Discussionmentioning
confidence: 99%